Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form.
• People who have been formally diagnosed with multiple myeloma according to recognised international diagnostic guidelines.
• People whose disease is measurable through blood or urine tests showing certain abnormal protein levels, or through specific abnormal light chain levels in the blood.
• People who have already received between 1 and 5 previous treatment courses, including three specific types of therapy: a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a CD38 antibody treatment (confirm with trial site for exact treatment history requirements).
• People whose multiple myeloma has been shown to be getting worse after their most recent treatment, based on recognised international criteria.
• People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale, meaning they are fully active to capable of limited self-care (confirm with trial site).
• People whose blood counts, liver function, kidney function, and electrolyte (mineral) levels in the blood meet the minimum thresholds required by the trial (confirm with trial site for specific values).
• People with no history of another cancer in the past 5 years, with the exception of certain skin cancers that have been successfully treated.
• People who are able to attend all required study visits and follow the study requirements.

Who may not be able to join:

• People who are currently receiving other cancer treatments at the same time.
• People who have had chemotherapy, radiation therapy, or major surgery within the 4 weeks before starting this study.
• People who are currently in another clinical trial involving an experimental drug, or who have been in one within the past 4 weeks.
• People who have any condition or abnormal test result that could make it unsafe for them to participate or make it difficult to interpret the study results.
• People who have active involvement of multiple myeloma in the brain or spinal fluid, or who are showing signs of this.
• People diagnosed with plasma cell leukaemia, Waldenström's macroglobulinaemia, or POEMS syndrome.
• People who have had dental surgery (including tooth extraction), significant gum disease, mouth injury, or poorly fitting dentures within the 6 months before the first dose of the study drug.
• People who have received certain bone-strengthening medications (bisphosphonates or denosumab) within 6 weeks before the first dose of the study drug.
• Male participants who are not willing to use a condom during the study period and until the end of treatment, or who are not willing to avoid donating sperm during that time.
• People who are pregnant or currently breastfeeding.
• Female participants who are able to become pregnant and are not willing to use a highly effective form of contraception throughout the study treatment period (confirm with trial site for the full list of accepted contraceptive methods).
• People for whom pre-treatment medications including dexamethasone, antihistamine, and paracetamol would not be medically appropriate.

Important: Always verify eligibility with the trial site directly before applying.